High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 777-783

  Karachalias, Nikolaus ^a   Babaei Jadidi, Roya ^a   Kupich, Christian ^a   Ahmed, Naila ^a   Thornalley, Paul J ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

Benfotiamine; Cholesterol; Diabetes; Dyslipidemia; Glycation; Methylglyoxal; Thiamine; Triglycerides

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE DERIVATIVE; BENFOTIAMINE; CHOLESTEROL; GLYOXAL; INSULIN ZINC SUSPENSION; LYSINE DERIVATIVE; METHYLGLYOXAL; N CARBOXYETHYLLYSINE; N CARBOXYMETHYLLYSINE; PLASMA PROTEIN; STREPTOZOCIN; THIAMINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; RAT; STREPTOZOCIN DIABETES; THIAMINE DEFICIENCY;

EID: 23744478659     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.090     Document Type: Conference Paper

References (30)

1. AMERICAN DIABETES ASSOCIATION. 2004. Dyslipidemia management in adults with diabetes. Diabetes Care 27: S71.
2. GRANT, P.J. 2003. The genetics of atherothrombotic disorders: a clinician's view. J. Thromb. Haemost. 1: 1381-1390.
3. LEHTO, S., T. RONNEMAA, K. PYORALA & M. LAAKSO. 1999. Poor glycemic control predicts coronary heart disease in patients with type 1 diabetes without nephropathy. Arterioscler. Thromb. Vasc. Biol. 19: 1014-1019.
4. FORREST, K.Y.Z., D.J. BECCKER, L.H. KULLER, et al. 2000. Are predictors of coronary heart disease and lower extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis 148: 159-169.
5. STEVENS, R., R.L. COLEMAN, A.I. ADLER, et al. 2004. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Diabetes Care 27: 201-207.
6. HENRY, R.M.A., O. KAMP, P.J. KOSTENSE, et al. 2004. Left ventricular mass increases with deteriorating tolerance, especially in women: independence of increased arterial stiffness or decreased flow-mediated dilation. The Hoorn Study. Diabetes Care 27: 522-529.
7. TASKINEN, M.-R. 2004. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46: 733-749.
8. BABAEI-JADIDI, R., N. KARACHALIAS, N. AHMED, et al. 2003. Prevention of incipient diabetic nephropathy by high-dose thiamine and Benfotiamine. Diabetes 52: 2110-2120.
9. STRACKE, H., H.P. HAMMES, D. WERKMANN, et al. 2001. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp. Clin. Endocrinol. Diabetes 109: 330-336.
10. HAMMES, H.-P., X. DU, D. EDELSTEIN, et al. 2003. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med. 9: 294-299.
11. BABAEI-JADIDI, R., N. KARACHALIAS, C. KUPICH, et al. 2004. High dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats Diabetologia 47: 2235-2246.
12. DEGENHARDT, T.P., N.L. ALDERSON, D.D. ARRINGTON, et al. 2002. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61: 939-950.
13. KUSUNOKI, J., K. ARAGANE, T. KITAMINE, et al. 2000. Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activity. Arterioscler. Thromb. Vasc. Biol. 20: 171-178.
14. HILBIG, R. & H. RAHMANN. 1998. Comparative autoradiographic investigations on the tissue distribution of benfotiamine vs. thiamine in mice. Arzneimittelforschung 48: 461-468.
15. WAKABAYASHI, Y. 1978. Purification and properties of porcine thiamine pyrophosphokinase. Vitamins 52: 223-236.
16. AHMED, M.U., S.R. THORPE & J.W. BAYNES. 1986. Identification of Nε-carboxymethyl-lysine as a degradation product of fructoselysine in glycated protein. J. Biol. Chem. 261: 4889-4894.
17. HOLLAN, S., H. FUJII, A. HIRONO, et al. 1993. Hereditary triosephosphate isomerase (TPI) deficiency: two severely affected brothers-one with and one without neurological problems. Hum. Genet. 92: 486-490.
18. SCHWARZENBOLZ, U., T. HENLE, R. HAEBNER & A. KLOSTERMEYER. 1997. On the reaction of glyoxal with proteins. Z. Lebens. Unters. Forsch. 205: 121-124.
19. THORNALLEY, P.J., S. BATTAH, N. AHMED, et al. 2003. Quantitative screening of advanced glycation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375: 581-592.
20. ODANI, H., K. IIJIMA, M. NAKATA, et al. 2001. Identification of Nω-carboxymethyl-arginine, a new advanced glycation end product, in serum proteins of diabetic patients: possibly a new marker of aging and diabetes. Biochem. Biophys. Res. Commun. 285: 1232-1236.
21. THORNALLEY, P.J. 1998. Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact. 111-112: 137-151.
22. YOSHINO, K., S. SAITO, M. SANO, et al. 1996. Formation of methylglyoxal in reduced nicotinamide adenine dinucleotide phosphate-dependent lipid peroxidation of rat liver microsomes. Jpn. J. Toxicol. Environ. Health 42: 236-240.
23. AHMED, N. & P.J. THORNALLEY. 2002. Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with aminoquinolyl-N-hydroxysuccimidyl-carbamate and intrinsic fluorescence. Biochem. J. 364: 15-24.
24. PORTERO-OTIN, M., M.J. BELLMUNT, J.R. REQUENA & R. PAMPLONA. 2003. Protein modification by advanced Maillard adducts can be modulated by dietary polyunsaturated fatty acids. Biochem. Soc. Trans. 31: 1403-1405.
25. AHMED, N., O.K. ARGIROV, H.S. MINHAS, et al. 2002. Assay of advanced glycation end products (AGEs): surveying AGEs by chromatographic assay with derivatization by aminoquinolyl-N-hydroxysuccimidyl-carbamate and application to Nε-carboxymethyl-lysine- and Nε-(1-carboxyethyl)lysine-modified albumin. Biochem. J. 364: 1-14.
26. JOHNSON, R.N., R.W. EASDALE, M. TATNELL & J.R. BAKER. 1991. Significance of variation in turnover of glycated albumin on indices of diabetic control. Clin. Chim. Acta 198: 229-238.
27. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986.
28. ALDERSON, N.L., M.E. CHACHICH, N.N. YOUSSEF, et al. 2003. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 63: 2123-2133.
29. SAITO, N., M. KIMURA, A. KUCHIBA & Y. ITOKAWA. 1987. Blood thiamine levels in outpatients with diabetes mellitus. J. Nutr. Sci. Vitaminol. 33: 421-430.
30. HAVIVI, E., H. BAR ON, A. RESHEF & I. RAZ. 1991. Vitamins and trace metals status in noninsulin-dependent diabetes mellitus. Internat. J. Vit. Nutr. Res. 61: 328-333.